Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

Increased Risk of Ischemic Stroke in Multiple Myeloma Associated With Lenalidomide Treatment: A Case Report and Review of the Literature.

de Celis E, Alonso de Leciñana M, Rodríguez-Pardo J, Fuentes B, Díez-Tejedor E.

Clin Neuropharmacol. 2018 Sep 28. doi: 10.1097/WNF.0000000000000310. [Epub ahead of print]

PMID:
30273192
2.

H3K4me3 mediates the NF-κB p50 homodimer binding to the pdcd1 promoter to activate PD-1 transcription in T cells.

Redd PS, Lu C, Klement JD, Ibrahim ML, Zhou G, Kumai T, Celis E, Liu K.

Oncoimmunology. 2018 Jul 23;7(9):e1483302. doi: 10.1080/2162402X.2018.1483302. eCollection 2018.

PMID:
30228953
3.

Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice.

Sultan H, Wu J, Kumai T, Salazar AM, Celis E.

Cancer Immunol Immunother. 2018 Jul;67(7):1091-1103. doi: 10.1007/s00262-018-2164-6. Epub 2018 Apr 25.

PMID:
29696308
4.

Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition.

Sultan H, Kumai T, Fesenkova VI, Fan AE, Wu J, Cho HI, Kobayashi H, Harabuchi Y, Celis E.

Cancer Immunol Res. 2018 May;6(5):617-627. doi: 10.1158/2326-6066.CIR-17-0549. Epub 2018 Feb 26.

PMID:
29483127
5.

Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.

Zhu W, Peng Y, Wang L, Hong Y, Jiang X, Li Q, Liu H, Huang L, Wu J, Celis E, Merchen T, Kruse E, He Y.

Hepatology. 2018 Aug;68(2):574-589. doi: 10.1002/hep.29844. Epub 2018 Jun 12.

PMID:
29443377
6.

Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer.

Veglia F, Tyurin VA, Mohammadyani D, Blasi M, Duperret EK, Donthireddy L, Hashimoto A, Kapralov A, Amoscato A, Angelini R, Patel S, Alicea-Torres K, Weiner D, Murphy ME, Klein-Seetharaman J, Celis E, Kagan VE, Gabrilovich DI.

Nat Commun. 2017 Dec 14;8(1):2122. doi: 10.1038/s41467-017-02186-9.

7.

Effective antitumor peptide vaccines can induce severe autoimmune pathology.

Sultan H, Trillo-Tinoco J, Rodriguez P, Celis E.

Oncotarget. 2017 Jul 29;8(41):70317-70331. doi: 10.18632/oncotarget.19688. eCollection 2017 Sep 19.

8.

Cancer immunotherapy: moving forward with peptide T cell vaccines.

Kumai T, Fan A, Harabuchi Y, Celis E.

Curr Opin Immunol. 2017 Aug;47:57-63. doi: 10.1016/j.coi.2017.07.003. Epub 2017 Jul 19. Review.

9.

Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition.

Abu Eid R, Ahmad S, Lin Y, Webb M, Berrong Z, Shrimali R, Kumai T, Ananth S, Rodriguez PC, Celis E, Janik J, Mkrtichyan M, Khleif SN.

Cancer Res. 2017 Aug 1;77(15):4135-4145. doi: 10.1158/0008-5472.CAN-16-1925. Epub 2017 Jun 14.

10.

Cancer immunotherapy without frontiers: 2nd Annual Immuno-Oncology Meeting of the Centro de Investigación de Cancer en Sonora (CICS), Ciudad Obregón, Sonora México, Dec 2-4, 2016.

Gallardo-Rincón D, Marquez JP, Celis E.

Cancer Immunol Immunother. 2017 Sep;66(9):1243-1247. doi: 10.1007/s00262-017-2009-8. Epub 2017 May 8.

11.

Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.

Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, Ueda S, Takahara M, Kumai T, Ishibashi K, Kosaka A, Aoki N, Oikawa K, Uno Y, Akiyama N, Sado M, Takei H, Celis E, Harabuchi Y, Kobayashi H.

Cancer Immunol Immunother. 2017 Jul;66(7):877-890. doi: 10.1007/s00262-017-1987-x. Epub 2017 Mar 27.

PMID:
28349165
12.

Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.

Guo G, Yu M, Xiao W, Celis E, Cui Y.

Cancer Res. 2017 May 1;77(9):2292-2305. doi: 10.1158/0008-5472.CAN-16-2832. Epub 2017 Mar 9.

13.

Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.

Ohkuri T, Kosaka A, Ishibashi K, Kumai T, Hirata Y, Ohara K, Nagato T, Oikawa K, Aoki N, Harabuchi Y, Celis E, Kobayashi H.

Cancer Immunol Immunother. 2017 Jun;66(6):705-716. doi: 10.1007/s00262-017-1975-1. Epub 2017 Feb 27.

PMID:
28243692
14.

Evidence-based guides in tracheostomy use in critical patients.

Raimondi N, Vial MR, Calleja J, Quintero A, Cortés Alban A, Celis E, Pacheco C, Ugarte S, Añón JM, Hernández G, Vidal E, Chiappero G, Ríos F, Castilleja F, Matos A, Rodriguez E, Antoniazzi P, Teles JM, Dueñas C, Sinclair J, Martínez L, Von der Osten I, Vergara J, Jiménez E, Arroyo M, Rodriguez C, Torres J, Fernandez-Bussy S, Nates JL.

Med Intensiva. 2017 Mar;41(2):94-115. doi: 10.1016/j.medin.2016.12.001. Epub 2017 Feb 7. English, Spanish.

15.

Evidence-based guidelines for the use of tracheostomy in critically ill patients.

Raimondi N, Vial MR, Calleja J, Quintero A, Cortés A, Celis E, Pacheco C, Ugarte S, Añón JM, Hernández G, Vidal E, Chiappero G, Ríos F, Castilleja F, Matos A, Rodriguez E, Antoniazzi P, Teles JM, Dueñas C, Sinclair J, Martínez L, von der Osten I, Vergara J, Jiménez E, Arroyo M, Rodríguez C, Torres J, Fernandez-Bussy S, Nates JL; FEPIMCTI and LACCTIN.

J Crit Care. 2017 Apr;38:304-318. doi: 10.1016/j.jcrc.2016.10.009. Epub 2016 Oct 20.

PMID:
28103536
16.

Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.

Kumai T, Lee S, Cho HI, Sultan H, Kobayashi H, Harabuchi Y, Celis E.

Cancer Immunol Res. 2017 Jan;5(1):72-83. doi: 10.1158/2326-6066.CIR-16-0194. Epub 2016 Dec 9.

17.

Peptide vaccines in cancer-old concept revisited.

Kumai T, Kobayashi H, Harabuchi Y, Celis E.

Curr Opin Immunol. 2017 Apr;45:1-7. doi: 10.1016/j.coi.2016.11.001. Epub 2016 Dec 9. Review.

18.

Editorial: A matter of survival: HMGB1 regulates autophagy in tumor MDSC.

Kumai T, Celis E, Rodriguez PC.

J Leukoc Biol. 2016 Sep;100(3):447-9. doi: 10.1189/jlb.3CE0216-091R. No abstract available.

PMID:
27587376
19.

Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy.

Ishibashi K, Kumai T, Ohkuri T, Kosaka A, Nagato T, Hirata Y, Ohara K, Oikawa K, Aoki N, Akiyama N, Sado M, Kitada M, Harabuchi Y, Celis E, Kobayashi H.

Oncoimmunology. 2016 Mar 30;5(6):e1169356. doi: 10.1080/2162402X.2016.1169356. eCollection 2016 Jun.

20.

Designing therapeutic cancer vaccines by mimicking viral infections.

Sultan H, Fesenkova VI, Addis D, Fan AE, Kumai T, Wu J, Salazar AM, Celis E.

Cancer Immunol Immunother. 2017 Feb;66(2):203-213. doi: 10.1007/s00262-016-1834-5. Epub 2016 Apr 6. Review.

21.

T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy.

Raber PL, Sierra RA, Thevenot PT, Shuzhong Z, Wyczechowska DD, Kumai T, Celis E, Rodriguez PC.

Oncotarget. 2016 Apr 5;7(14):17565-78. doi: 10.18632/oncotarget.8197.

22.

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment.

Sharma MD, Shinde R, McGaha TL, Huang L, Holmgaard RB, Wolchok JD, Mautino MR, Celis E, Sharpe AH, Francisco LM, Powell JD, Yagita H, Mellor AL, Blazar BR, Munn DH.

Sci Adv. 2015 Nov 6;1(10):e1500845. doi: 10.1126/sciadv.1500845. eCollection 2015 Nov.

23.

Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma.

Kumai T, Ohkuri T, Nagato T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Celis E, Harabuchi Y, Kobayashi H.

Sci Rep. 2015 Nov 5;5:16280. doi: 10.1038/srep16280.

24.

An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects.

Cho HI, Jung SH, Sohn HJ, Celis E, Kim TG.

Oncoimmunology. 2015 May 26;4(11):e1043504. eCollection 2015 Nov.

25.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

26.

STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice.

Wang Z, Celis E.

Cancer Immunol Immunother. 2015 Aug;64(8):1057-66. doi: 10.1007/s00262-015-1713-5. Epub 2015 May 19.

27.

Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.

Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, Woods DM, Barrios K, Powers J, Sahakian E, Wang HW, Canales J, Marante D, Smalley KSM, Bergman J, Seto E, Kozikowski A, Pinilla-Ibarz J, Sarnaik A, Celis E, Weber J, Sotomayor EM, Villagra A.

Mol Oncol. 2015 Aug;9(7):1447-1457. doi: 10.1016/j.molonc.2015.04.002. Epub 2015 Apr 24.

28.

c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma.

Kumai T, Matsuda Y, Ohkuri T, Oikawa K, Ishibashi K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H.

Oncoimmunology. 2015 Mar 6;4(2):e976077. eCollection 2015 Feb.

29.

CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.

Kumai T, Nagato T, Kobayashi H, Komabayashi Y, Ueda S, Kishibe K, Ohkuri T, Takahara M, Celis E, Harabuchi Y.

Cancer Immunol Immunother. 2015 Jun;64(6):697-705. doi: 10.1007/s00262-015-1675-7. Epub 2015 Mar 10.

30.

Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells.

Ortiz ML, Kumar V, Martner A, Mony S, Donthireddy L, Condamine T, Seykora J, Knight SC, Malietzis G, Lee GH, Moorghen M, Lenox B, Luetteke N, Celis E, Gabrilovich D.

J Exp Med. 2015 Mar 9;212(3):351-67. doi: 10.1084/jem.20140835. Epub 2015 Feb 9.

31.

Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents.

Zaidi S, Blanchard M, Shim K, Ilett E, Rajani K, Parrish C, Boisgerault N, Kottke T, Thompson J, Celis E, Pulido J, Selby P, Pandha H, Melcher A, Harrington K, Vile R.

Mol Ther. 2015 May;23(5):845-856. doi: 10.1038/mt.2014.253. Epub 2014 Dec 29.

32.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

33.

NF-κB is crucial in proximal T-cell signaling for calcium influx and NFAT activation.

Bronk CC, Yoder S, Hopewell EL, Yang S, Celis E, Yu XZ, Beg AA.

Eur J Immunol. 2014 Dec;44(12):3741-6. doi: 10.1002/eji.201444904. Epub 2014 Oct 22.

34.

Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor.

Kumai T, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H.

J Transl Med. 2014 Sep 21;12:265. doi: 10.1186/s12967-014-0265-3.

35.

A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway.

Nagato T, Celis E.

Oncoimmunology. 2014 May 15;3:e28440. eCollection 2014.

36.

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.

Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, Witt R, Masters G, Bauer T, Gabrilovich DI.

J Clin Invest. 2014 Jun;124(6):2626-39. doi: 10.1172/JCI74056. Epub 2014 May 1.

37.

Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53.

Kumai T, Ishibashi K, Oikawa K, Matsuda Y, Aoki N, Kimura S, Hayashi S, Kitada M, Harabuchi Y, Celis E, Kobayashi H.

Cancer Immunol Immunother. 2014 May;63(5):469-78. doi: 10.1007/s00262-014-1533-z. Epub 2014 Mar 15.

PMID:
24633296
38.

Oxidized lipids block antigen cross-presentation by dendritic cells in cancer.

Ramakrishnan R, Tyurin VA, Veglia F, Condamine T, Amoscato A, Mohammadyani D, Johnson JJ, Zhang LM, Klein-Seetharaman J, Celis E, Kagan VE, Gabrilovich DI.

J Immunol. 2014 Mar 15;192(6):2920-31. doi: 10.4049/jimmunol.1302801. Epub 2014 Feb 19. Erratum in: J Immunol. 2014 May 15;192(10):4935. Tuyrin, Vladimir A [corrected to Tyurin, Vladimir A]; Cao, Wei [removed].

39.

Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity.

Dougan SK, Dougan M, Kim J, Turner JA, Ogata S, Cho HI, Jaenisch R, Celis E, Ploegh HL.

Cancer Immunol Res. 2013 Aug;1(2):99-111. doi: 10.1158/2326-6066.CIR-13-0047.

40.

Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.

Nagato T, Lee YR, Harabuchi Y, Celis E.

Clin Cancer Res. 2014 Mar 1;20(5):1223-34. doi: 10.1158/1078-0432.CCR-13-2781. Epub 2014 Jan 3.

41.

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.

Kumai T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H.

Br J Cancer. 2013 Oct 15;109(8):2155-66. doi: 10.1038/bjc.2013.577. Epub 2013 Sep 17.

42.

Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance.

Hopewell EL, Zhao W, Fulp WJ, Bronk CC, Lopez AS, Massengill M, Antonia S, Celis E, Haura EB, Enkemann SA, Chen DT, Beg AA.

J Clin Invest. 2013 Jun;123(6):2509-22. doi: 10.1172/JCI67250. Epub 2013 May 1.

43.

Endometriosis of the lung: report of a case and literature review.

Huang H, Li C, Zarogoulidis P, Darwiche K, Machairiotis N, Yang L, Simoff M, Celis E, Zhao T, Zarogoulidis K, Katsikogiannis N, Hohenforst-Schmidt W, Li Q.

Eur J Med Res. 2013 May 1;18:13. doi: 10.1186/2047-783X-18-13. Review.

44.

Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.

Yu Y, Cho HI, Wang D, Kaosaard K, Anasetti C, Celis E, Yu XZ.

J Immunol. 2013 Feb 15;190(4):1873-81. doi: 10.4049/jimmunol.1201989. Epub 2013 Jan 11.

45.

BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses.

Cho HI, Barrios K, Lee YR, Linowski AK, Celis E.

Cancer Immunol Immunother. 2013 Apr;62(4):787-99. doi: 10.1007/s00262-012-1382-6. Epub 2012 Dec 25.

46.

Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

Huynh AS, Chung WJ, Cho HI, Moberg VE, Celis E, Morse DL, Vagner J.

J Med Chem. 2012 Nov 26;55(22):9751-62. doi: 10.1021/jm301002f. Epub 2012 Nov 8.

47.

Vaccine-elicited CD8+ T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice.

Lee S, Stokes KL, Currier MG, Sakamoto K, Lukacs NW, Celis E, Moore ML.

J Virol. 2012 Dec;86(23):13016-24. doi: 10.1128/JVI.01770-12. Epub 2012 Sep 26.

48.

Polyphenol-SiO2 hybrid biosorbent for heavy metal removal. Yerba mate waste (Ilex paraguariensis) as polyphenol source: kinetics and isotherm studies.

Copello GJ, Pesenti MP, Raineri M, Mebert AM, Piehl LL, de Celis ER, Diaz LE.

Colloids Surf B Biointerfaces. 2013 Feb 1;102:218-26. doi: 10.1016/j.colsurfb.2012.08.015. Epub 2012 Aug 19.

PMID:
23006564
49.

Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy.

Ramakrishnan R, Huang C, Cho HI, Lloyd M, Johnson J, Ren X, Altiok S, Sullivan D, Weber J, Celis E, Gabrilovich DI.

Cancer Res. 2012 Nov 1;72(21):5483-93. doi: 10.1158/0008-5472.CAN-12-2236. Epub 2012 Aug 31.

50.

A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope.

Kobayashi H, Kumai T, Hayashi S, Matsuda Y, Aoki N, Sato K, Kimura S, Celis E.

Cancer Immunol Immunother. 2012 Dec;61(12):2215-25. doi: 10.1007/s00262-012-1284-7. Epub 2012 May 26.

PMID:
22638550

Supplemental Content

Support Center